Evidence map›Paper›PMID 41706877›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

T-cadherin, a major adiponectin binding partner, suppresses ERK signaling in metabolic tissues.

Hirofumi Nagao, Yuta Kondo, Keitaro Kawada, Yuya Fujishima, Shunsuke Shiode, Yuhei Uehara, Shiro Fukuda, Yoshinari Obata, Shunbun Kita, Hitoshi Nishizawa and 1 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hirofumi NagaoDepartment of Metabolism and Atherosclerosis, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565-0871, Japan.ORCID 0009-0001-1261-4160
Yuta KondoDepartment of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565-0871, Japan.ORCID 0009-0008-9236-4114
Keitaro KawadaDepartment of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565-0871, Japan.
Yuya FujishimaDepartment of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565-0871, Japan.
Shunsuke ShiodeDepartment of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565-0871, Japan.ORCID 0009-0007-7682-0602
Yuhei UeharaDepartment of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565-0871, Japan.
Shiro FukudaDepartment of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565-0871, Japan.ORCID 0000-0003-0712-7154
Yoshinari ObataDepartment of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565-0871, Japan.ORCID 0000-0002-3443-3635
Shunbun KitaDepartment of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565-0871, Japan.ORCID 0000-0002-8937-0053
Hitoshi NishizawaDepartment of Metabolism and Atherosclerosis, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565-0871, Japan.
Iichiro ShimomuraDepartment of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565-0871, Japan.

Funding

Japan Diabetes Society (JDS) Junior Scientist Development GrantLotte Foundation Lotte Research Promotion GrantManpei Suzuki Diabetes Foundation Manpei Suzuki Diabetes FoundationMEXT | Japan Society for the Promotion of Science (JSPS) 23K19589MEXT | Japan Society for the Promotion of Science (JSPS) 24K02504MEXT | Japan Society for the Promotion of Science (JSPS) 24K19305Mochida Memorial Foundation for Medical and Pharmaceutical Research ( ) Mochida Memorial Foundation for Medical and Pharmaceutical ResearchMSD Life Science Foundation, Public Interest Incorporated Foundation (SD Life Science Foundation) MSD Life Science FoundationSenri Life Science Foundation Senri Life Science FoundationSuzuken Memorial Foundation (SMF) Suzuken Memorial Foundation
6 · The paper itself

Abstract

T-cadherin, which is a major adiponectin binding partner, exerts various organ-protective effects. However, the specific changes in intracellular signaling that are induced by T-cadherin in metabolic tissues/cells remain unclear. We demonstrated that T-cadherin suppresses ERK signaling in both cultured cells and murine tissues. T-cadherin knockdown increased ERK phosphorylation in C2C12 myocytes and F2 endothelial cells, whereas T-cadherin overexpression suppressed ERK phosphorylation. Proteomic analysis revealed that many proteins that are downstream targets of ERK signaling were upregulated by T-cadherin knockdown in myocytes. T-cadherin knockdown in myocytes or knockout in heart or skeletal muscles altered the levels of membrane proteins that are involved in signal transduction, including IGF1R and EGFR. Ablation of T-cadherin in mice was accompanied by increased ERK signaling, leading to increased cardiac hypertrophy and decreased appropriate muscle atrophy during starvation. Thus, T-cadherin, whose protein expression is maintained by adiponectin, modulates intracellular signaling and regulates cardiac and skeletal muscle homeostasis in addition to promoting exosome production by adiponectin.

Indexed as

AdiponectinCadherinsMAP Kinase Signaling SystemAnimalsCardiomegalyCell LineErbB ReceptorsMiceMice, KnockoutMuscle, SkeletalMyocardiumPhosphorylationReceptor, IGF Type 1AdiponectinCadherinsErbB ReceptorsH-cadherinIgf1r protein, mouseReceptor, IGF Type 1adiponectinERKGPI-anchorIGF-1 receptorT-cadherin

Identifiers

PMID41706877
PMCPMC12933100

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.